Company Showcases Translational Oncology Platform at Houston Gathering of Investors and Industry Leaders
Houston, TX – 2024 — Avesta Bio was selected to present at the 2024 Texas Life Science Forum, a premier annual event convening biotechnology executives, venture capital firms, institutional investors, and strategic partners from across the region and nationally.
The Texas Life Science Forum highlights emerging life sciences companies advancing innovative therapeutic platforms and clinical development programs. Companies selected to present are recognized for scientific merit, development readiness, and potential clinical impact.
During the presentation, Avesta Bio outlined its approach to targeting fundamental cellular stress-response and drug-resistance pathways implicated in tumor progression. The company also provided an overview of its translational strategy, intellectual property position, and roadmap toward early-phase clinical development.
“We were honored to be selected to present at the Texas Life Science Forum,” said Ian Akash Morrison, CEO of Avesta Bio. “Texas continues to play an important role in fostering life sciences innovation, and we value the opportunity to engage with investors and industry leaders committed to advancing rigorous, mechanism-driven therapeutic development.”
The invitation reflects growing interest in Avesta Bio’s platform strategy and its disciplined approach to translating foundational biology into clinical-stage oncology programs. The company continues to expand its engagement across the Texas biotechnology ecosystem as it advances toward key regulatory and clinical milestones.
About Avesta Bio
Avesta Bio is a translational oncology company developing first-in-class therapies that target fundamental cellular stress-response and drug-resistance pathways. By correcting maladaptive cellular programs implicated in cancer progression, the company aims to deliver safe and effective treatments for patients with high-unmet-need malignancies.
The company is advancing its lead therapeutic program through strategic partnerships supporting IND-enabling studies, GMP manufacturing, and early-phase clinical development.
For more information, visit: www.avestabio.com